Lack of effectiveness of several chelators in removing internally deposited strontium from mice following repeated parenteral strontium administration

Vet Hum Toxicol. 1992 Feb;34(1):7-9.

Abstract

Diethylenetriaminepentaacetic acid (DTPA), ethylenglycolbis-(beta-amino-ethylether)-N,N-tetraacetic acid (EGTA), tartaric acid, KRYPTOFIX 222, and KRYPTOFIX 5 were evaluated for their efficacy in mobilization of strontium from the body of mice which had received 20 sc injections of strontium nitrate (95 mg/kg/injection) for 4 w. Twenty-four hours after the last strontium injection, ip administration of 1 of the various chelators or 0.9% saline was initiated and continued daily for 5 d. Mice were housed in metabolic cages, and urine and feces were collected daily for 5 d. After this period, the animals were killed and tissues removed. Tartaric acid, KRYPTOFIX 222, and KRYPTOFIX 5 had no effect on urinary or fecal strontium elimination, whereas DTPA and EGTA significantly decreased the fecal strontium excretion. The concentration of strontium in bone was only lowered in tartaric-treated mice. This study indicates the use of the above chelators is not an effective treatment to enhance the removal of strontium following repeated parenteral strontium administration.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Bridged Bicyclo Compounds / therapeutic use
  • Bridged Bicyclo Compounds, Heterocyclic*
  • Chelating Agents / therapeutic use*
  • Chelation Therapy*
  • Egtazic Acid / therapeutic use
  • Ethers, Cyclic / therapeutic use
  • Feces / chemistry
  • Male
  • Mice
  • Pentetic Acid / therapeutic use
  • Strontium / metabolism*
  • Tartrates / therapeutic use

Substances

  • Bridged Bicyclo Compounds
  • Bridged Bicyclo Compounds, Heterocyclic
  • Chelating Agents
  • Ethers, Cyclic
  • Tartrates
  • cryptating agent 222
  • Egtazic Acid
  • 1,11-bis(8-quinolinyloxy)-3,6,9-trioxaundecane
  • Pentetic Acid
  • tartaric acid
  • Strontium